A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 198-207

  Sempere, Lorenzo F ^a   Gunn, Jason R ^a   Korc, Murray ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Epidermal growth factor (EGF); Extracellular matrix; Matrigel ; Pancreatic adenocarcinoma (PDAC); Soft agar; Transforming growth factor (TGF ); Tumor microenvironment

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; AGAR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; MATRIGEL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; EXTRACELLULAR MATRIX; GROWTH STIMULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; BENZAMIDES; CARCINOMA, PANCREATIC DUCTAL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CULTURE MEDIA; DEOXYCYTIDINE; DIOXOLES; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX; HUMANS; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MICROENVIRONMENT;

EID: 79961226547     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.15979     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60:277-300; DOI: 10.3322/caac.20073.
2. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009; 27:5660-9; DOI: 10.1200/JCO.2009.21.9022.
3. Preis M, Korc M. Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther 2010; 9:754-63; DOI: 10.4161/cbt.9.10. 11534.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; DOI: 10.1200/JCO.2006.07.9525.
5. Maitra A, Hruban RH. Pancreatic Cancer. Annu Rev Pathol 2008; 3:157-88; DOI: 10.1146/annurev.pathmechdis.3.121806.154305.
6. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003; 2:8; DOI: 10.1186/1476-4598-2-8.
7. Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007; 194:S84-6; DOI: 10.1016/j.amjsurg.2007.05.004.
8. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105:1846-56. (Pubitemid 24002804)
9. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002; 1:161-7.
10. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001; 7:2931-40. (Pubitemid 32911404)
11. Vonlaufen A, Phillips PA, Xu Z, Goldstein D, Pirola RC, Wilson JS, et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res 2008; 68:7707-10; DOI: 10.1158/0008-5472.CAN-08-1132.
12. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6:1186-97; DOI: 10.1158/1535-7163.MCT-06- 0686.
13. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6:506-20; DOI: 10.1038/nrc1926.
14. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10:415-24; DOI: 10.1038/nrc2853.
15. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20:3130-46; DOI: 10.1101/gad.1478706.
16. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006; 20:3147-60; DOI: 10.1101/gad.1475506.
17. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11:229-43; DOI: 10.1016/j.ccr.2007.01.017.
18. Arteaga CL. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 2006; 16:30-7; DOI: 10.1016/j.gde.2005.12.009.
19. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554-67; DOI: 10.1038/nri2808.
20. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-68; DOI: 10.1016/S1046-2023(03)00032-X.
21. Gutierrez-Barrera AM, Menter DG, Abbruzzese JL, Reddy SA. Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. Biochem Biophys Res Commun 2007; 358:698-703; DOI: 10.1016/j.bbrc.2007.04.166.
22. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439:798-802. (Pubitemid 33141325)
23. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442:444-52. (Pubitemid 36718311)
24. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996; 67:283-8; DOI: 10.1002/(SICI)1097-0215(19960717)67:23.0.CO;2-B.
25. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006; 66:95-106; DOI: 10.1158/0008-5472.CAN-05-2168.
26. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17:3112-26; DOI: 10.1101/gad.1158703.
27. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4:437-50; DOI: 10.1016/S1535-6108(03)00309-X.
28. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69:5820-8; DOI: 10.1158/0008-5472.CAN-08- 2819.
29. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15:489-500; DOI: 10.1016/j.ccr.2009.03.022.
30. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5:675-88; PubMed DOI: 10.1038/nrc1695.
31. Ghajar CM, Bissell MJ. Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 2008; 130:1105-18; DOI: 10.1007/s00418-008-0537-1.
32. Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene 2010; 29:3335-48; DOI: 10.1038/onc.2010.112.
33. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Srcfocal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 2009; 69:475-82; DOI: 10.1158/0008-5472.CAN-08-2649.
34. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122:35-43; DOI: 10.1007/s10549-009-0502-2.
35. Arany PR, Rane SG, Roberts AB. Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition. Oncogene 2008; 27:2507-12; DOI: 10.1038/sj.onc.1210889.
36. Kleeff J, Wildi S, Friess H, Korc M. Ligand induced upregulation of the type II transforming growth factor (TGFbeta) receptor enhances TGFbeta responsiveness in COLO-357 cells. Pancreas 1999; 18:364-70; DOI: 10.1097/00006676-199905000-00006.
37. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998; 17:1969-78; DOI: 10.1038/sj.onc.1202118.
38. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M. Smad6 suppresses TGFbeta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999; 255:268-73; DOI: 10.1006/bbrc.1999.0171.
39. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, et al. The TGFbeta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18:5363-72; DOI: 10.1038/sj.onc.1202909.
40. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58:5329-32. (Pubitemid 28551110)
41. Korc M. Aberrant Transforming Growth Factor-beta. Signaling in Human Pancreatic Cancer: Translational Implications. In: Jakowlew SB (Ed.). Cancer Drug Discovery and Development: Transforming Growth Factor-β in Cancer Therapy: Cancer Treatment and Therapy. Humana Press Inc., Totowa, NJ 2008; 2:523-35.
42. Wagner M, Kleeff J, Friess H, Buchler MW, Korc M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 1999; 19:370-6; DOI: 10.1097/00006676-199911000-00008.
43. Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16:4246-55; DOI: 10.1158/1078-0432.CCR-10-1152.
44. Gu G, Brown JR, Melton DA. Direct lineage tracing reveals the ontogeny of pancreatic cell fates during mouse embryogenesis. Mech Dev 2003; 120:35-43; DOI: 10.1016/S0925-4773(02)00330-1.
45. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, et al. Both p16(Ink4a) and the p19(Arf) -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103:5947-52; DOI: 10.1073/pnas.0601273103.
46. Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 2009; 69:422-30; DOI: 10.1158/0008-5472.CAN-08-1290.